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ABSTRACT Ataxia telangiectasia (A-T) is a rare, progressive, multisystem disease that has a large
number of complex and diverse manifestations which vary with age. Patients with A-T die prematurely
with the leading causes of death being respiratory diseases and cancer. Respiratory manifestations include
immune dysfunction leading to recurrent upper and lower respiratory infections; aspiration resulting from
dysfunctional swallowing due to neurodegenerative deficits; inefficient cough; and interstitial lung disease/
pulmonary fibrosis. Malnutrition is a significant comorbidity. The increased radiosensitivity and increased
risk of cancer should be borne in mind when requesting radiological investigations. Aggressive proactive
monitoring and treatment of these various aspects of lung disease under multidisciplinary expertise in the
experience of national multidisciplinary clinics internationally forms the basis of this statement on the
management of lung disease in A-T. Neurological management is outwith the scope of this document.
@ERSpublications
Complex respiratory manifestations in ataxia telangiectasia require regular, proactive
multidisciplinary management http://ow.ly/Solqe
Introduction
Ataxia telangiectasia (A-T) (Louis-Bar syndrome; OMIM 208900) is an autosomal recessive disorder caused
by mutations in the gene ATM (ataxia-telangiectasia mutated) (11q22.3). This gene is expressed ubiquitously
and encodes a protein kinase (ATM kinase) which plays a key role in the control of double-strand-break
DNA repair. The Orphanet registry estimates the average prevalence of A-T at 1/100000 children [1].
The most reliable estimates for the number of people with A-T, in the UK at least, are 3 per million [2], and
hence individual clinicians are likely to have limited experience in treating the disease. The prevalence of
patients with A-T in Europe is estimated to be 1/150000 [3]. In Europe, 410 living A-T patients are currently
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listed on the European Society for Immunodeficiencies registry [4]. A clinician faced with a patient or family
with a child with A-T will want to access the requisite experience, expertise, advice and ongoing research,
and to make appropriate referrals. It is important that patients and professionals obtain appropriate expert
advice and recommendations on the management of this rare condition.
A-T is a progressive, multisystem disease that has a large number of complex and diverse manifestations
that vary with age (table 1).
The clinical picture of this condition can be very variable and the severity of the pulmonary, immunological
and neurological manifestations varies widely between patients and is related to the severity of the
underlying mutations and any residual ATM kinase activity [5]. It has been recently suggested that the
name A-T should be replaced by ATM syndrome. ATM syndrome represents a neurodegenerative disorder
with multisystem involvement due to the absence or reduced levels of ATM protein and kinase activity [6].
The syndrome is characterised by the presence of movement disorders, such as cerebellar ataxia, dystonia,
chorea and myoclonus, in association with systemic abnormalities such as immunodeficiency, malignancies,
oculocutaneous telangiectasias and an increase in α-fetoprotein levels. The disease most commonly presents
with ataxia during the third or fourth year of life. The important first step in the evaluation of young
children presenting with ataxia should be α-fetoprotein testing. The diagnosis should then be confirmed by
genetic testing to identify the mutations and measure the product of the ATM gene, the protein kinase
ATM. This diagnostic test is likely to be available in specialised laboratories only.
Patients with A-T die prematurely, the leading causes of death being respiratory diseases and cancer. A
minimally estimated annual mortality rate for white patients is 19.5/1000 for ages 15–19 years and reportedly
three-fold higher for African-American patients [7]. In two large cohorts of patients with A-T, one prospective
(median age at death estimated by a modification of the Kaplan–Meier survival curve) and one retrospective,
median survival was 25 years and 19 years, respectively. There was a wide range of age at death. Mortality
crossed the 25th and 75th centiles in the prospective cohort at ages 18 years and 28 years, and at ages 14 years
and 28 years in the retrospective cohort. In these two cohorts, life expectancy did not correlate well with
severity of neurological impairment [8]. The large French registry study showed that the prognosis for patients
with A-T has not changed since 1954, with the Kaplan–Meier 20-year survival rate reported as 53.4% [9].
Scope of the article
This article examines the respiratory aspects of A-T, including chronic and recurrent infections;
bronchiectasis and interstitial lung disease (ILD); immunodeficiency associated with A-T; and aspiration
TABLE 1 Clinical manifestations of ataxia telangiectasia
Respiratory# Recurrent respiratory tract infections including otitis media, sinusitis,
bronchitis and pneumonia
Bronchiectasis secondary to recurrent/chronic infection and aspiration
Interstitial lung disease
Obliterative bronchiolitis
Aspiration syndromes due to incoordinate swallowing
Opportunistic infections
Restrictive lung disease due to scoliosis, neuromuscular disease or
fibrosis
Immunodeficiencies Clinically not apparent in all patients
Variable degrees
Generally nonprogressive
IgA and IgG2 deficiency most common
Low total IgG and IgE also seen
Poor polysaccharide antibody responses
Variable cellular immunodeficiency (low numbers of T- and B-cells)
Increased risk of malignancy Mainly lymphoid tumours (in patients aged <16 years)
Lymphoid and nonlymphoid tumours in older patients
Neurological¶ Neurodegeneration of the cerebellum
Progressive cerebellar ataxia
Oculomotor apraxia
Movement disorders: chorea, dystonia
Other¶ Ocular, cutaneous and mucosal telangiectasias
Accelerated ageing
Diabetes mellitus
#: there are no pulmonary telangiectasias; ¶: not reviewed in this article.
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syndromes due to incoordinate swallowing. The management of the ataxia itself and developmental delay
is outside the scope of the article.
We aim to categorise the phenotypes of lung disease, examine the natural history and describe current
best-practice monitoring and treatment strategies for various aspects of lung disease. There are no
randomised controlled trials with respect to the treatment of the respiratory complications in A-T. This
paper serves as a consensus statement which summarises current evidence and best practice, and aims to
set out the future translational, epidemiological and clinical research agenda. Accordingly, we are not able
to formally evaluate the evidence using GRADE (Grading of Recommendations Assessment, Development
and Evaluation) (http://taskforces.ersnet.org/about-task-forces/item/how-to-apply-for-ers-funding).
Methods
This multidisciplinary European Respiratory Society (ERS) task force comprises a broad range of
experienced clinicians (respiratory, infectious diseases, immunology, neurology and genetics fields,
physiotherapists and a speech and language therapist) as well as a patient representative from the national
UK patient charity for A-T (L. Yarlett, who is the parent of a young person with A-T and chairman of the
board of trustees of the A-T Society). This document was created by combining a firm evidence-based
approach where available and the clinical expertise of the task force members. However, a formal grading
of the evidence was not performed, and therefore, this document does not contain recommendations for
clinical practice. The process adopted for this statement was agreed by all task force members. Each
member was requested to frame important clinical questions for the management of lung disease in A-T.
The literature searches were carried out by S. Zinna based on the questions framed and they covered the
years from 2000 to 2015. In addition, the references of the selected papers were scrutinised for further
relevant evidence. Hand searches of A-T clinical research conference abstract books were made by
S. Zinna and J. Bhatt. Publications that were in print in English were selected for further examination.
Observational studies (no published systematic reviews or randomised controlled trials) from MEDLINE/
PubMed, Embase, the Cochrane Central Register of Controlled Trials, CINAHL (Cumulative Index to
Nursing and Allied Health Literature) and the Cochrane Collaboration were collected. The scientific
evidence relevant to the delegated subject area was reviewed. Results were discussed by all members of the
task force. The final document was written by the chairs of the task force ( J. Bhatt and P. Merkus). The
draft manuscripts were reviewed by all task force members to ensure appropriateness and relevance, and
the final document was accepted by all task force members.
Phenotypes of respiratory disease in A-T
Aetiology, natural history and physical examination
There are three recognised major lung disease phenotypes. 1) Immune dysfunction leading to recurrent
upper and lower respiratory tract infections (RTIs), which in turn can lead to bronchiectasis; 2) lung
disease associated with dysfunctional swallow and inefficient cough due to neurodegenerative deficits,
which increases the risk for aspiration and consequently may also cause or worsen bronchiectasis; and
3) ILD/pulmonary fibrosis.
There is a significant overlap in the initial presenting symptoms of the phenotypes described above. For
example, chronic or intermittent chest congestion with a wet/moist cough may be due to cough
impairment with difficulty clearing airway secretions, or related to infections secondary to immune
deficiency, but could also be due to aspiration. In contrast, ILD usually causes a dry cough with associated
tachypnoea, crackles, hypoxaemia and finger clubbing in the absence of viral or bacterial infections.
Immune deficiency
This is multifactorial, with both reduction of circulating T- and B-cell numbers (caused by reduced thymic
output and increased apoptosis) and abnormal lymphocyte function (restricted antigen receptor repertoires,
abnormal B-cell class switching and disturbed naive B- and T-cell homeostasis) contributing to the clinical
phenotype [10, 11]. The variable severity of antibody deficiency is related to disturbed naive B- and T-cell
homeostasis, probably because of reduced B- and T-cell production linked to disturbed V(D)J gene segment
recombination, and consequently a limited B- and T-cell receptor repertoire. There is also a reduction of
T-cell-dependent memory B-cell populations [11]. The most common humoral immunological defects are
markedly diminished or absent serum IgA and IgG2, and impaired antibody responses to vaccines [12].
Serum IgG level can be normal even when some IgG subclasses are reduced, although a subset of classical
A-T patients (⩽10%) will have a severe early-onset hypogammaglobulinaemia [13] and increased IgM levels
[14]. The A-T patients with increased serum IgM levels show a remarkably more severe disease course [12].
Patients with IgG2 or IgG4 deficiency appear to be at a higher risk of RTIs [15]. The patients with classical
A-T generally have two truncating mutations resulting in total absence of ATM kinase activity, while patients
with milder phenotypes have at least one missense or splice site mutation resulting in the expression of ATM
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with some kinase activity (see the section on phenotype/genotype correlation). Patients with variant A-T
have a later onset of disease and less severe antibody deficiency [5, 10, 11].
Cellular immunity can also be affected in A-T: abnormal development of the thymus, with absence of
Hassall’s corpuscles and corticomedullary differentiation, impaired delayed hypersensitivity reactions or
lymphoproliferative responses to mitogens and diminishing numbers of CD4 lymphocytes [16]. T-cell
lymphopenia is a commonly observed laboratory finding in people with A-T, but its clinical significance
remains unclear, and the fact that A-T patients do not show susceptibility to classical opportunistic
infection, for example with Pneumocystis jirovecii, remains poorly understood.
Response to immunisations
Routine childhood immunisations, including attenuated live viral vaccines, would usually have been given
prior to the diagnosis of A-T and/or recognition of associated immunodeficiency [12]. Reports of adverse
events in patients with A–T after the administration of live vaccines are rare, and for the most part
vaccines are well-tolerated [17].
Patients with A-T are capable of making protective antibodies to routine childhood (conjugated) vaccines
such as diphtheria and tetanus, but the response to the 23-valent pneumococcal polysaccharide vaccine
(PPV) appears to be variable. NOWAK-WEGRZYN et al. [12] reported that 69% of patients showed protective
levels of antibody for all tested serotypes in response to PPV, while other studies have reported poor
antibody response to this immunisation [18, 19]. Immune response to the 7-valent pneumococcal conjugate
vaccine (PCV) appears to be sufficient, with two- to 7.5-fold increases over baseline after immunisation for
all seven serotypes [20]. A follow-up booster dose with PPV after PCV seems to augment the response to
antibody levels to the PPV23, though the increases in pneumococcal antibody titres from baseline were
lower (1.5- to seven-fold increase) in A-T patients than controls (nine- to 34-fold increase) [19].
Inactivated influenza vaccine is usually given to all patients with A-T and their close family contacts; there
are no data available on the live attenuated nasal influenza vaccine, but as mentioned above other live
attenuated viral vaccines have been tolerated in children with A-T [12]. This is usually offered even to
those prescribed immunoglobulin replacement therapy, as the administered immunoglobulin may not
contain specific antibodies against the antigens of the seasonal influenza viruses [16]. Varicella zoster
vaccine (VZV) is also offered to those who have not already experienced chickenpox and are nonimmune
and in those who are not profoundly immunocompromised. Post-exposure prophylaxis with VZV
immunoglobulin and aciclovir are usually considered in those who are profoundly immune-suppressed
[16]. Human papilloma virus vaccine is an inactivated vaccine, which on theoretical grounds is particularly
important for girls with A-T in view of the apparent abnormal response to papilloma viruses causing
cutaneous warts, and the general predisposition to malignant disease including carcinomas. Bacille
Calmette–Guerin vaccine is not used routinely, but can be considered for use in those patients with an
increased risk of tuberculosis exposure (depending on geographical area and origin of parents from
tuberculosis-endemic countries), unless there is profound T-cell lymphocytopenia [21].
Laboratory abnormalities and clinical infections
NOWAK-WEGRZYN et al. [12] found no correlation between frequency of RTIs and deficiency of IgG, IgA or
subclasses of IgG.
Types of infections
Several retrospective case series (both published [8, 15, 20, 22] and unpublished (S. Zielen, Dept of
Allergology, Pneumology and Cystic Fibrosis, Children’s Hospital, Goethe-University Theodor-Stern Kai,
Frankfurt/Main, Germany; personal communication)) have shown a high prevalence of recurrent and
chronic upper and lower RTI, the latter becoming more prevalent with increasing age. Definitions of
recurrent infections did vary in these reports, e.g. recurrent respiratory infections as five or more
respiratory manifestations (other than pneumonia) per year or one episode of pneumonia in a year [23] or
more than three respiratory infections per winter season requiring antibiotics or a severe/atypical response
to a single infection [10]. Preliminary results from a small prospective study found highly significant
differences for children with A-T (median (range) 11 (2–25) years) and age-matched controls in symptom
scores, number of episodes, days with symptoms and missed days of kindergarten, school or work.
However, severe infections with hospitalisation were surprisingly low in prevalence, but prolonged cough
after viral infections was frequently present in patients with A-T (S. Zielen; personal communication).
Radiologically confirmed bronchiectasis seems to be established by the end of first decade [9, 17, 23]. The
prevalence of bronchiectasis varied from 10% [17] to 47% [23] in these series. The experiences of
members of the task force suggest that proactive monitoring and aggressive multidisciplinary treatment
delays the onset or stabilises bronchiectasis.
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Microbiology of lung disease in A-T
Not all studies had microbiological confirmation of infection [9, 10, 12, 22], and even when this was
available, the nature of the samples obtained was heterogeneous (nasopharyngeal aspirate, throat swabs,
cough swabs, sputum or bronchoalveolar lavage or serological confirmation on blood tests) [17, 23, 24].
Sputum microscopy and culture in children who can cough and produce sputum [23] and cough swabs in
those who cannot [24] are usually carried out at each visit. Sputum induction in nonexpectoring patients
or bronchoalveolar lavage (which, being invasive, is a last resort) are sometimes required in children with
troublesome respiratory symptoms but negative microbiology results [23].
Viruses
Respiratory infections are common in A-T during the early childhood years [12, 23] although the overlap
with normal age-related susceptibility to early viral infections can be difficult to tease out. The common
respiratory viruses can be detected even at scheduled nonurgent clinic visits [24]; however the role and
impact of viral infections in A-T remain to be determined.
Bacteria
Pulmonary infections in A-T are usually caused by common bacterial pathogens in later childhood, such
as Haemophilus influenzae, Streptococcus pneumoniae, Pseudomonas aeruginosa and Staphylococcus
aureus. The airways of younger patients with A-T were found to be more likely to be colonised with
S. aureus, H. influenzae or S. pneumoniae, and over time, these colonising pathogens were replaced by
mucoid P. aeruginosa [12, 17, 23, 24].
Opportunistic infections
These are uncommon in patients with A-T. Most reported series have found no evidence of any
opportunistic pathogens and even when reported, they are uncommon [9, 12, 17, 24].
The microbiology of the respiratory tract in patients with A‐T is thus unlike that of other primary
immune deficiencies and has more similarities to that seen in patients with cystic fibrosis [17]. Other
similarities to cystic fibrosis are that systemic spread of infectious organisms is rare, opportunistic
infections are not observed and bronchiectasis and pneumothoraces are common results of recurrent
pulmonary insults [17, 23].
Does immune deficiency progress?
The immune system in A-T is probably abnormal from birth. There have been only a few reports of
patients with progressive immunodeficiency [25, 26]. A retrospective study [12] found no difference in the
prevalence of Ig deficiencies over time. A-T patients do not appear to have increased frequency or greater
severity of immune abnormalities with age and, in general, for the majority of patients the severity of
immune deficiency (both clinically and in terms of immunological blood markers [11]) does not seem to
deteriorate significantly. If recurrent respiratory tract infections present later in life, then other
contributory factors (e.g. cough/swallowing difficulties, neuromuscular abnormalities or underlying lung
disease) are a more likely explanation [27].
Immune replacement and prophylactic antibiotic therapy
No placebo-controlled trials have been performed with regards to prophylactic antibiotic therapy or
immune replacement therapy.
Antibiotics
RTIs affect patient survival and are an independent risk factor for mortality in A-T. There is a large
variation in the practice of prescribing prophylactic antibiotics for patients with A-T. A large registry study
[9] suggested that antibiotic prophylaxis (effective against encapsulated bacteria, such as H. influenzae and
S. pneumoniae) might be beneficial at early stages of the disease, but this is based on an extrapolation
from other immunodeficiency diseases. A high proportion (74%) of children with A-T are prescribed
prophylactic antibiotics [24] on inconsistent and non-evidence-based criteria. A longitudinal follow-up
study (mean duration of follow-up 5 years) found that 30 (68%) out of 44 patients were commenced early
on prophylactic antibiotics with an aim to reduce the frequency and severity of bacterial respiratory
infections [27]. The proportion of patients with A-T who had chronic respiratory symptoms and were
using chronic macrolide antibiotics was lower in the patients in the USA (12 out of 36 A-T patients alive
and 0 out of 65 A-T patients who died secondary to lung disease); however comparative data for patients
with A-T who did not have chronic respiratory symptoms were not available [17].
There are no controlled trials that provide evidence of eradication of P. aeruginosa colonisation/infection
[24] in A-T. Anecdotally and using the approach taken in cystic fibrosis, a combination of oral
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ciprofloxacin and nebulised colistin seems to be favoured by clinicians. In those with more advanced
disease, combination intravenous antipseudomonal antibiotics are often used.
Prophylactic antibiotic treatment is considered on an individual basis when the burden of respiratory
infections is high, but microbiological resistance and side-effects should be always borne in mind.
Immunoglobulin replacement
The decision to commence Ig replacement therapy is taken on clinical grounds in those children who have
a history of recurrent respiratory infections and low specific antibody responses despite booster
immunisations [16]. Patients with borderline low serum IgG concentrations for age but protective
antibody responses to childhood vaccines and no history of severe or recurrent infections do not need to
be on replacement therapy [12]. Hence there is wide variation in the proportion of patients who are on
replacement treatment (table 2).
In the series from the USA [12] the median (range) age at initiation of i.v. Ig therapy was 4 (1.9–10.7)
years. Recurrent respiratory infections decreased in frequency, duration and severity [12, 23] and all
children reported that i.v. Ig increased their general wellbeing [23]. Supplemental Ig administration in
individuals with A-T was associated with lower forced vital capacity (FVC) % predicted. This association
may be due to a greater frequency of RTIs in those individuals with more severe immunodeficiency, thus
accounting for their lower pulmonary function. This is a clear bias since the more severe patients are
treated with i.v. Ig [28], as was also the case in the series by NOORDZIJ et al. [13], which included A-T
patients with hyper-IgM and severe immune deficiency. These findings suggest that the recognition of
groups who may be at higher risk of lower pulmonary function may help to direct care and improve
clinical outcomes in A-T. If Ig therapy is considered, most centres administer subcutaneous Ig, as is
currently recommended for severe immundeficiencies [29–31].
Interstitial lung disease
ILD was present in 25 (25.8%) out of 97 patients with A-T who had either chronic respiratory symptoms
or pulmonary disease listed as cause of death [32]. None of these patients had evidence of an infectious
process preceding the onset of their lung disease. Many of them had been previously treated for cancer.
The mean (range) age of onset of ILD was 17.5 (9–28) years. The signs and symptoms that preceded
radiographic evidence of ILD were a nonproductive cough in 21 out of 25 patients, dyspnoea in 12 out of
25 patients and fever in 11 out of 25 patients. All 10 patients who presented with a cough of >1 month’s
duration, dyspnoea, fever and abnormal auscultatory changes had interstitial changes on chest
radiography. None had lasting clinical improvement after treatment with antibiotics. ILD could be present
even in the absence of overt immune deficiency. The histological pattern of A-T ILD does not fit a specific
American Thoracic Society/ERS category among idiopathic interstitial pneumonias, and may represent a
unique class of ILD. The ILD of A-T is distinctive in its histology, which is uniquely characterised by lung
fibrosis and chronic inflammation with lymphocytic or lymphohistiocytic cells, and the presence of
atypical epithelial and interstitial cells with large hyperchromatic and pleiomorphic nuclei.
Bronchoalveolar lavage fluid contains >70% lymphocytes, 20% macrophages, <5% neutrophils and no
eosinophils or neoplastic cells [32]. The response to corticosteroids is discussed later [32].
Clinical examination often does not contribute to the diagnosis of ILD, as signs and symptoms are
nonspecific. Restrictive lung disease on pulmonary function testing may suggest the presence of an
interstitial process. A chest radiograph scan (fig. 1) is usually considered justifiable for any A-T patient
with pulmonary symptoms that do not remit fully after vigorous treatment of infection, because the
consequences of not imaging are much less than any concern that the patient may suffer tissue damage
TABLE 2 Replacement Ig replacement therapy in ataxia telangiectasia
Study design [ref.] Subjects n Subjects receiving Ig therapy (%)
Retrospective [10] 80 12.5#
Retrospective [12] 100 13
Retrospective [23] 15 60
Retrospective [9] 240 34.8¶
Retrospective [27] 44 15.9
Retrospective [28] 100 18.8
#: 17% of those with null mutations; ¶: 75.6% of the patients with bronchiectasis.
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from this dose of irradiation. Similarly, even high-resolution computed tomography (CT) (fig. 2) is usually
considered justifiable (although magnetic resonance imaging (MRI) could become the technique of choice,
as discussed later) as a prelude to a lung biopsy to confirm the diagnosis of ILD. However, the diagnostic
benefits of a procedure such as a lung biopsy should be weighed against the risks associated with
anaesthesia and surgery (see the later section on diagnostic and therapeutic radiation).
The aetiology and pathogenesis of ILD and pulmonary fibrosis in A-T patients is unknown. Various
potential triggers/contributors including atypical or viral infections and chronic aspiration, as well as the
effect of immune deficiency itself (ILD is well described in immune deficiency, albeit more typically as
part of the follicular bronchiolitis–lymphoid interstitial pneumonitis picture) may play a role. In the
largest reported series [32] no correlation was found between the development of ILD and abnormalities
in Ig levels. Those patients given chemotherapy appeared to have a different type of ILD with pulmonary
fibrosis dominating.
Only treatment with systemic corticosteroids early in the course of the illness was associated with clinical
and radiographic improvement. 19 out of 25 patients with ILD died within 24 months of disease onset. No
FIGURE 1 A plain chest radiograph of a patient with ataxia telangiectasia showing diffuse bibasal interstitial
changes.
FIGURE 2 Chest computed tomography scan of a patient with ataxia telangiectasia showing diffuse bibasilar
interstitial and interlobular reticular opacities with interlobular septal thickening, and bronchiectasis in the
right lower lobe. Note that any radiological imaging should use the minimum possible doses, and concerns
about radiosensitivity need to be addressed.
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patient who commenced treatment with systemic corticosteroids >1 year after the onset of interstitial
changes was alive, while five out of seven patients treated early with corticosteroids were alive at the time
of evaluation. Hence, a high degree of suspicion is warranted so that those patients with ILD can be
treated early and aggressively. The benefits of treatment with corticosteroids needs to be weighed up
against potential side-effects including inducing or aggravating diabetes or osteoporosis. The latter is
probably secondary to poor nutrition and early confinement to wheelchair. There is animal experimental
evidence that ATM deficiency leads to an osteoporotic phenotype in mice due to reduced bone formation
and increased bone resorption [33] or accelerated cellular ageing [34].
Other noninfective causes of diffuse lung diseases (which may mimic ILD) in A-T include pulmonary
parenchymal involvement secondary to lymphoma [35, 36] and pulmonary fibrosis secondary to
chemotherapy for the treatment of a malignancy [37]. The risk of rapid pulmonary decline following the
use of chemotherapeutic agents such as bleomycin is well described in A-T and may be due to an
underlying defect in injury repair [38]. These agents are used with great caution in A-T patients, if at all,
as they appear to have the same effect on cultured A-T homozygous cells as ionising radiation [39].
Lymphocytic interstitial pneumonitis has been reported as another cause of diffuse lung disease in A-T
and this responds to glucocorticosteroid treatment [40].
Respiratory monitoring
The underlying neurological involvement [41] can make it difficult to obtain reliable reproducible
dynamic lung function tests that require any effort and coordination. However, several researchers have
demonstrated that pulmonary function testing with certain modifications can be performed reliably and
reproducibly by patients with A-T so that it may be used to track the rate of decline in lung function over
time [23, 28, 41–43].
Standard spirometry
The reproducibility of testing is increased by stabilising the patient’s head and holding the cheeks while
the patient performs the forced expiratory manoeuvre, optimising the fit of the mouthpiece and assessing
for leaks in the system, and thus the majority of A-T adolescents are able to perform spirometry with
minimal modifications [41]. Flow–volume curves do meet recommended reproducibility criteria but often
fail to meet other standard recommendations for forced spirometry [43] and will often underestimate
respiratory function.
MCGRATH-MORROW et al. [41] found that most adolescents tested had normal functional residual capacity
(FRC), near-normal total lung capacity, high residual volume (RV), decreased vital capacity and low
maximal expiratory pressure, suggesting either or both expiratory muscle weakness and incoordination and
difficulty expiring to RV. Since the measurement of FRC requires only passive cooperation, they considered
this the most reliable lung measurement in individuals who may not be able to perform maximal inspiratory
and expiratory manoeuvres. As the vital capacity % pred values did not correlate with FRC % pred values,
the decreased vital capacity % pred values in the A-T adolescents may represent difficulty with complete
expiration (i.e. due to muscle weakness or coordination problems) rather than small lung volumes. Since
FVC predicted values in A-T are often low, the interpretation of sequential spirometry may best be
performed relative to an individual’s baseline study rather than compared to normal predicted values [43].
BERKUN et al. [42] studied a younger cohort of children with A-T (median (range) age 8.8 (3.7–19.3) years).
They found that the rise time to peak flow was three to four times longer than that of healthy values in most
of their patients (250–350 ms versus 70–80 ms in the healthy population). This delay in initiation of the
breath may not be due to obstructive lung disease per se, but in part secondary to neurological dysfunction
and delayed processing before initiating the expiratory breath. As (young) A-T patients often do not exhale
for more than 1 s, forced expiratory volume in 1 s (FEV1) may not be an accurate parameter for describing
bronchial obstruction in this particular group and FEV0.5 may be a better index [43].
Obstructive and mixed patterns are found in a small proportion of people with A-T [23, 28, 41, 42]. When
a reproducible obstructive pattern is observed on baseline flow–volume loops, bronchodilator reversibility
is assessed to determine whether bronchodilators and possibly inhaled corticosteroids would be beneficial.
Impulse oscillometry, a noninvasive test that can measure airway resistance, is an option in children who
are unable to perform spirometry reliably.
The possible causes of an obstructive pattern include suboptimal lung function testing through poor
coordination while breathing; bronchiectasis; small airways involvement due to infections with or without
aspiration; and asthma or other coincidental airways disease.
Inability to expire fully to RV and a short expiratory time may result in a decreased FVC, a high FEV1/FVC
ratio and the appearance of restrictive lung disease. If a restrictive pattern is suspected, this requires
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confirmation from assessment of total lung capacity and other static lung volumes (using body plethysmography
or a gas dilution technique). However, as many patients are dependent on wheelchairs and may be unable to
perform the required respiratory manoeuvres, body plethysmography is often not a practical option. If available,
helium dilution provides an effort-independent alternative for measuring lung volumes [44].
The possible causes of restrictive patterns include suboptimal lung function testing through poor
coordination while breathing, muscle fatigue, inspiratory muscle dysfunction, ILD and scoliosis or other
chest wall deformity.
MCGRATH-MORROW et al. [28] explored several potential factors associated with lower lung function in A-T.
They found that females aged ⩾11 years, males who had higher chromosomal breakage and the need for
supplemental γ-globulin were associated with lower FVC % pred, but body mass index (BMI) percentile or
gastric tube placement for nutritional supplementation were not. Some reassurance is offered by the
observation that in a subset of 25 people who underwent pulmonary function testing on more than one
occasion over an average of 2 years, there was no significant decline.
Gas exchange
Diffusing capacity of the lung for carbon monoxide (DLCO) measurements are sometimes considered,
particularly to provide evidence of impaired gas exchange when evaluating a patient for ILD. However,
advanced A-T disease is associated with severe neurodegenerative dysfunction and such tests, especially the
single-breath DLCO measurement may simply not be feasible; measurement of DLCO by rebreathing
technique may be required. Therefore, there are arguments for monitoring alternative end-points closely,
such as clinical condition (respiratory rate and effort and auscultation), transcutaneous oxygen saturation
at rest (and during exercise or overnight oxygen saturations if possible).
Young adults with more advanced lung disease are monitored for worsening type 2 respiratory failure by
assessing for hypercapnia by either capillary blood gases or end-tidal carbon dioxide monitoring. Chronic
respiratory insufficiency was present in eight children (mean±SD arterial oxygen tension 78±5 mmHg) at a
mean age of 10 years. Alveolar hypoventilation was also diagnosed in two patients (mean arterial carbon
dioxide tension <52 mmHg; normal range 35–45 mmHg) [23].
Studies into peripheral airway function in A-T are lacking.
Sleep-related breathing disorder
As the neurological condition progresses and decreased pulmonary reserve develops in the late teens,
sleep-related breathing problems may contribute to respiratory morbidity. MCGRATH-MORROW et al. [45]
performed overnight polysomnography on 12 adolescents with A-T at a median (range) age of 16 (13–
20) years. All subjects in the study were wheelchair-bound and the median (range) FVC was 44 (16–82)%
pred. The authors found that the majority of A-T adolescents unexpectedly had infrequent partial or
complete upper airway obstructions during sleep and minimal night-time hypoxaemia. Subjects did have
decreased sleep efficiency, probably due in part to their underlying neurological condition. No correlation
was found between FVC and sleep efficiency in the A-T subjects, unlike subjects with cystic fibrosis where
the magnitude of sleep disruption is associated with severity of lung disease (low FEV1), but is not directly
correlated with the degree of nocturnal hypoxaemia or hypoventilation [46]. There are no studies on the
use of noninvasive ventilation in A-T for sleep-related breathing disorder, but extrapolating from other
neuromuscular diseases, if there is evidence of abnormal gas exchange or sleep fragmentation then
supplemental oxygen or noninvasive ventilation support should be considered [44].
Cough and mucociliary clearance
Some aspects of lung disease seen in A-T may be attributable to progressive neurological decline. Coordinated
and maximal inspiratory and expiratory efforts are needed to generate effective cough and to clear airway
secretions. Breathing and coughing involve cyclic motor acts that require cerebellar coordination (which is
impaired in A-T) and it is likely that disordered muscle control (in addition to muscle weakness) exacerbates the
decline in respiratory function. Abnormal respiratory muscle function resulting from neurological decline can
lead to decreased tidal volumes and ineffective cough [41]. A decline in maximal respiratory muscle function has
been found to be a marker for disease progression and respiratory failure in A-T patients [41]. Clinical indicators
of lung disease due to impairment of upper airway and respiratory muscle systems may include chronic weak or
dyscoordinate cough and prolonged or difficult recovery from respiratory illnesses. Lack of conditioning in
patients with A-T who are wheelchair-bound may contribute to the deterioration in lung function.
In children and adolescents with neuromuscular weakness, those with inspiratory vital capacity <1.1 L were
shown to be at increased risk of hospitalisation due to lower RTIs [44]. Hence, measurements of vital capacity
can also be used as surrogate markers for respiratory muscle strength. From this standpoint, A-T patients are
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approached in much the same way as those with other diseases causing neuromuscular impairment, such as
Duchenne muscular dystrophy (DMD) and spinal muscular atrophy, although incoordination and fatigue are
more significant contributors to lung disease in A-T, in addition to muscle weakness.
Evaluation of maximum inspiratory and expiratory pressures (MIP and MEP, respectively) is a
well-established marker of respiratory muscle strength and coordination [47].
Respiratory muscle strength training (RMST) focuses on increasing the force-generating capacity of the
inspiratory and expiratory muscles [48] when disease progression leads to worsening respiratory status
with dyscoordinate and impaired cough and mucociliary clearance (aspiration due to swallowing
dysfunction). Very scant A-T-specific data are available, but a recent longitudinal study assessed
spirometry, subjective sensation of dyspnoea, MIP, MEP and quality of life before and after a 24-week
inspiratory muscle training programme in 11 A-T patients and nine healthy volunteers. It was shown that
inspiratory muscle training was effective in improving ventilatory pattern, lung volume, respiratory muscle
strength and the health and vitality domains of quality of life in patients with A-T. Inspiratory muscle
training may be an effective adjunct therapy to drug treatment for patients with A-T [49]. Whether or not
swallow safety to reduce aspiration improves after RMST, as has been shown for some other
neurodegenerative conditions was not evaluated in this study [50].
Mucociliary clearance is impaired following recurrent infections and aspiration, both commonly seen in A-T.
The resulting mucosal damage and secondary ciliary dyskinesia further impairs secretion clearance. Airway
clearance physiotherapy, as used in cystic fibrosis or primary ciliary dyskinesia may mobilise mucus in the
lower airways. Measures to improve pulmonary clearance and prevent atelectasis are likely to be beneficial in
A-T patients, especially those with more advanced neurological decline, as they have both impaired mucociliary
and cough clearance. Again, this is extrapolation from evidence and experience from other chronic respiratory
conditions, although even in these it cannot be said that the evidence base is stellar. Such interventions include
the use of chest physiotherapy, flutter valve therapy and cough assist devices. As in other neuromuscular
disease disorders, regimens may be increased during episodes of acute illness [51, 52]. A-T patients have
significantly lower inspiratory volume prior to cough, FVC cough, peak cough flow, peak cough flow to peak
expiratory flow ratio and number of spikes per manoeuvre than healthy controls [53]. Additionally, although
peak cough flow increased with age, the yearly rate of increase was significantly lower than normal. Thus, A-T
patients had a weak cough compared to healthy controls of similar ages and cough worsened with age [53].
Cough assist devices (I. Sarouk, The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center,
Ramat-Gan, Israel; personal communication) were used with some success in a small study where three out of
five patients showed significant improvement in FVC, peak cough flow and mid-expiratory flows.
Physiotherapy advice regarding which techniques to adopt to optimise airway clearance before irreversible
structural lung damage occurs is desirable, although there is no firm evidence base to give specific advice
for A-T. Some form of regular exercise, even in younger children who are still mobile and not yet on a
downward trajectory of pulmonary and neurological decline, is usually advised to parents and carers by
most experts who look after children with A-T.
There are no studies into the efficacy of nebulised hypertonic saline, rhDNase, or inhaled mannitol on
mobilisation of mucus in A-T. In AT-patients in general, inhalation therapy is likely to be less effective
because of the neurological aspects of the disease. Extrapolating from studies in other groups of patients
(non-cystic fibrosis bronchiectasis or airway malacia), it is likely but not certain that rhDNase is probably
ineffective. Hypertonic saline or inhaled mannitol may offer some benefit in some patients [54] and this is
supported by anecdotes of n=1 clinical trials for these medications in carefully selected patients and the
experience of experts who look after children with A-T.
Genotype/phenotype correlation in A-T
It has been known for some time that there is heterogeneity of disturbances of immunoregulatory
mechanisms in A-T and FIORILLI et al. [55] postulated that the presence or absence of the ATM protein best
explained the clinical heterogeneity and immunodeficiency. More recent work has confirmed this and has
shown that patients with mutations resulting in a demonstrated complete loss of ATM kinase activity were
significantly more likely to suffer from recurrent respiratory infections and have a greater need for
prophylactic antibiotics, compared with those with leaky splice site or missense mutations resulting in
expression of either some normal or mutant residual kinase activity. These results suggested that small
amounts of preserved ATM function protects against the development of immune deficiency [10, 11]. MICOL
et al. [9] in a large French registry study classified mutations according to the expected functional activity of
the ATM product as either complete loss of expression or activity (class A or null) or reduced expression or
some residual activity (class B or hypomorphic). They found RTIs to be the main risk factor for mortality
among patients with hypomorphic mutations in ATM, while those with null mutations have a higher risk for
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cancer (mainly haematological malignancies) at younger ages. They hypothesised that RTIs increased
mortality in patients with a hypomorphic mutation compared with those with two null mutations; this could
probably be explained by the later onset of cancer in the group with hypomorphic mutations [9]. However, it
is important to note that in a large cohort of children with early clinical onset the ATM protein was absent,
showing that the classical phenotype is present in most children with A-T [56].
Nutritional effects on lung disease and immune function
Several small cross-sectional studies have shown that patients with A-T exhibit high rates of malnutrition, short
stature and reduced lean body mass [56–59] (E. Stewart, et al., Nottingham Children’s Hospital, UK Paediatric
National Clinic, Nottingham University Hospitals, NHS Trust, Nottingham, UK; personal communication). A
high percentage (58%) of A-T patients had a BMI below the third percentile, despite apparently adequate
energy intake especially until early adolescence, and this may reflect underlying hypercatabolism due to
oxidative stress and inflammation [57]. There is a progressive reduction in the BMI with increasing age [57, 59]
(E. Stewart et al.; personal communication). The onset of malnutrition depends on the relationship between
nutrient balance and nutrient requirement, and a patient with A-T either loses weight or fails to grow normally
if their absorbed energy intake is less than their total daily energy expenditure. Numerous factors including
neurodegeneration, limited food intake with progressive disease, dysphagia and/or swallowing incoordination,
limited physical activity, hormonal changes, hypogonadism, insulin resistance, glucose intolerance, abnormal
expression of insulin-like growth factor-1 (somatomedin C) and low levels of insulin-like growth factor binding
protein-3, infections and an associated hypercatabolic state all contribute to poor growth [56, 60]. In cystic
fibrosis, lung inflammation appears to be related to increases in resting metabolic rate. Acute exacerbations of
the chronic lung disease increases resting metabolic rate, which returns to a basal level some weeks after the
inflammation is treated [61]; similar factors are likely (but not proven) to be contributory in A-T. A-T causes
extreme insulin resistance [62], but clinical diabetes seems to be diagnosed infrequently [63–66]; in a Turkish
series of 160 patients somatic growth retardation was reported to be common, but only two patients had frank
diabetes mellitus [67]. It is unclear whether the presence of diabetes also affects lung disease in any way, but
diabetes should be borne in mind during peri-operative management (see later).
An anthropometric assessment based on simple measurements, such as weight and height, is insufficient
to identify changes in body composition. Using more accurate assessment of body cell mass (BCM) by
methods such as bioimpedance assessment [59] (Pommering, Dept of Nutrition and Dietetics, The Royal
Brisbane & Women’s Hospital, Brisbane, Queensland, Australia; personal communication), the prevalence
of malnutrition in A-T patients was found to be high (69%). Of particular note, three children identified
as overweight or obese using standard anthropometry were identified as malnourished (n=2) or moderately
BCM-depleted (n=1), and BCM depletion worsened with age whereby all participants aged >9 years were
identified as malnourished [59].
Worsening nutritional status increases infection-related morbidity and mortality [68].
In children, malnutrition is of particular concern since it adversely affects not only statural growth but may also
impact lung development [69]. Gastrostomy may be required to improve the quality and quantity of nutrition,
reduce aspiration-related risks and improve the quality of life related to mealtimes in people with A-T [70].
Dyscoordinate swallowing, aspiration, gastro-oesophageal reflux and gastrostomy
Impairment in bulbar muscle function can lead to swallowing dysfunction and chronic aspiration, which can
cause and exacerbate lung disease [71, 72]. In A-T, dysphagic problems commonly emerge in the second decade
of life [72]. However, unlike individuals with neuromuscular disorders such as DMD and spinal muscular
atrophy, in patients with A-T the reason for aspiration is a dyscoordinate swallow that is multifactorial rather
than due to primary muscle weakness. Ataxia, hyperkinesis and bulbar dysfunction due to cerebellar
involvement all lead to dyscoordination of the oral motor and swallowing movements. In the experience of the
task force members, unlike the neuromuscular dystrophy patients who have problems with thick consistencies
because of a weak swallow [73], children with A-T are observed to have problems with thin consistencies, and
this has been shown by videofluoroscopic swallow study (VFSS) evaluation [71], which reported that aspiration
occurred most frequently when older patients were drinking thin liquids through a straw.
Cough or congestion with meals may suggest dysfunctional swallow and aspiration. Poor weight gain may
be an indicator of excessive caloric expenditure due to the increased work of breathing or difficulty taking
in adequate calories [56–58].
Fatigue, while not measurable or well delineated in clinical research, is characteristic for A-T patients and
may further contribute to aspiration and inefficient cough. Oropharyngeal dysphagia with aspiration is
common and appears to be progressive in older patients (second decade) with A-T. The onset of dysphagia
appears to coincide with a decrease in nutritional status although in a cross-sectional study it was not
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possible to distinguish between nutritional deficiency as a cause or effect of the dysphagia [71]. Neither the
presence nor absence of coughing during mealtimes was found to be a reliable indicator of airway
contamination during swallowing, as silent aspiration occurred in 71% of the patients whose aspiration was
detected on videofluoroscopy. VFSS is the gold standard for assessing potential abnormalities of the
pharyngeal phase of swallowing, which can only be inferred from a clinical observation. Radiographic
confirmation of swallowing dysfunction is often used for guiding treatment in the patient with A-T although
there is no universal consensus among task force members regarding this and some rely only on clinical
assessment including observation and neck auscultation during mealtimes. Judicious use of a VFSS protocol
that has been developed to capture dysphagic patterns while limiting radiation exposure is recommended
[71]. This was achieved by limiting the duration of the VFSS and studying only those older patients (mostly
children aged >9 years) with A-T with clinical evidence of oropharyngeal dysphagia (e.g. coughing or
choking during or between meals, excessive drooling or exceedingly long mealtimes defined as >40 min on
average) and/or recurrent RTIs or an otherwise unexplained drop in weight percentile or loss of weight.
Total videofluoroscopy time averaged ∼1 min per patient (range 40–90 s). This corresponds to an estimated
effective dose of 0.1 mSv (10 mrem) (a typical chest radiograph delivers an effective dose of 0.02–0.04 mSv)
[71]. To put this into perspective, the average annual dose of natural background radiation is 2.2 mSv in the
UK [74] or ∼3 mSv per year at sea level and 6 mSv at higher elevations, such as Denver, in the USA [75].
Regular reviews by a speech and language therapist are vital so that appropriate early advice for changes in
feeding routine such as elimination of thin liquids, pacing to slow the rate of liquid intake and having easily
chewable food, etc. can be made. Advice about body posture to maintain an upright stable position to avoid
shortening of the neck during eating and drinking is crucial. Ongoing concerns regarding aspiration and/or
adequacy of nutrition should prompt referral for gastrostomy insertion. In the LEFTON-GREIF et al. [70] series,
16% of patients underwent gastrostomy placement for nonpalliative reasons. This retrospective study
demonstrated that safe gastrostomy placement and caregiver satisfaction (easier mealtimes) can be achieved
when patients with A-T have feeding tubes placed at younger ages. While it is difficult to define the optimal age
for gastrostomy placement, significant progressive decline in weight, length and BMI z-scores appears to start
from the age of 8 years onwards (E. Stewart et al.; personal communication). Patients with childhood onset of
disease with predictable progression and impaired swallowing may benefit from early rather than late placement
of a feeding tube [70]. Even though a significant increase in weight or BMI z-score may not be seen following
gastrostomy insertion in A-T and other static or progressive severe neurological disorders, an almost universal
improvement in health-related quality of life scores is reported [70, 76]. Ease of medication administration as
well as feeding appears to have a positive impact on the child’s health at 6 and 12 months in the majority [76].
Additionally, delayed insertion of a gastrostomy is more likely to be associated with worse outcomes [70, 77].
Scoliosis in A-T
There have been no systematic studies of the incidence and natural history of scoliosis in A-T, although older
literature mentions that it is common [78]. Severe idiopathic scoliosis (6.7/1000) is also described among A-T
blood relatives [79] and may have a similar explanation as increased breast cancer risk in A-T carriers. Data
from the Nottingham clinic [21] show that significant scoliosis is present in 18 (22.5%) out of 80 patients.
The vast majority of patients with scoliosis have classical A-T; only two (11.1%) out of 18 patients with
scoliosis had atypical A-T. The age range at diagnosis of scoliosis is 5–19 years, it is equally common among
males and females and three (16.7%) out of 18 patients had severe scoliosis with two requiring spinal surgery.
Thus scoliosis is more common in adolescents as neurological disease progresses and patients spend
prolonged time in a wheelchair and have the tendency to lean on the same elbow, although it is not
possible to say if there is a cause–effect relationship, reverse causation or a mere association. Scoliosis
varies from mild to severe. In progressive neuromuscular disease it has been shown that scoliosis
aggravates restrictive lung disease due to an imbalance between the “load” or altered respiratory mechanics
and the “pump” or the respiratory muscle strength [80]. Maintaining assisted ambulation as long as
possible (e.g. use of walkers instead of wheelchairs) might prevent scoliosis and further deterioration of
lung function, but further studies are needed to sustain this clinical observation.
Risks of diagnostic radiation in A-T
Patients with all forms of A-T are unusually sensitive to therapeutic doses of ionising radiation [81]. In vitro,
fibroblasts and lymphoblasts from A-T homozygotes show increased sensitivity to ionising radiation and a
number of radiomimetic and free-radical producing agents [82, 83]. Increased cellular and chromosomal
radiosensitivity forms the basis of one of the highly sensitive and reasonably specific diagnostic tests used for
the diagnosis of A-T [84]. The available evidence for radiosensitivity in patients with A-T is based on
observations of patients who have received radiotherapy for the treatment of cancers before the diagnosis of
A-T was made. Exposure of children with A-T to therapeutic doses of ionising radiation has resulted in death
as a result of severe adverse reaction to the radiotherapy. However, there are no data available regarding the
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adverse effects of diagnostic radiography or CT scans in patients with A-T. In the absence of any evidence a
pragmatic approach is followed by most members of this task force for the use of diagnostic radiographic and
CT scans. Hence a single radiograph can be performed for diagnostic purposes such as the evaluation of
scoliosis because avoidance could result in delayed or missed diagnoses and necessary treatment. The clinician
and radiologist should consider the risks and benefits of each study and minimise radiation exposure as much
as possible; repeated radiography should be avoided, as even exposure to diagnostic X-rays in early life in the
general population is associated with increased risk of childhood leukaemia [85].
CT scanning provides excellent evaluation of the lungs, but the disadvantage of CT is the radiation exposure,
although technical innovations have enabled its reduction [86]. A single low-dose CT scan is sometimes
used, especially if ILD is suspected. Because radiation dose is directly proportional to the amount of the body
that is imaged, limiting CT scanning to a specific area of concern further reduces the dose. Where possible,
the smallest radiation dose should be used. Nonradiation imaging studies such as MRI scans or thoracic
ultrasound (the latter especially for pleural disease) are sometimes considered. MRI is not typically used for
the lungs due to the inability to visualise the air-filled alveoli; however, a diseased lung, e.g. areas of collapse
and consolidation, bronchiectasis and bronchial wall thickening [87] or with alveolar haemorrhage [88], can
be seen on MRI as a nonspecific airspace-filling process, similar to findings on a CT scan, and may provide
similar information to a CT scan without the increased radiation exposure; these modalities are increasingly
used. MRI with diffusion weighted imaging has been shown to be a reliable technique to detect lung
alterations in patients with various immunodeficiency diseases [89, 90]. CT scans and MRI findings were
comparable for moderate-to-severe degrees of bronchial and parenchymal alterations. Even for A-T, it has
been recently demonstrated for the first time that MRI can be valuable in the assessment of the extent and
severity of pulmonary changes in children and adults and is likely to become the modality of choice in the
future, especially if scan times can be shortened and resolution improved [91].
Cancer in A-T
A detailed discussion of cancer in A-T is beyond the scope of this article. ∼20% of A-T patients will
develop a malignancy during their lifetime. The vast majority of these are of lymphoid origin. There is no
consensus regarding the optimal strategy for treating children with A-T who develop haematopoietic
malignancies. Historically, many of these children have been treated with therapy that is much less
intensive than the conventional approach for non-A-T patients with similar malignancies (treatment
protocols utilising lower doses of radiation therapy and alternatives to radiomimetic drugs such as
bleomycin and neurotoxic agents, and modified chemotherapy protocols to avoid drugs that carry a high
risk of the child developing a second malignancy (topoisomerase inhibitors)). Although these less intensive
approaches may have stemmed from perceptions that these children would not tolerate intensive therapy,
there are in fact no data to support this view [21]. However, it is clear that children with A-T require a
modification in certain components of intensive therapy [21].
Perioperative management of a patient with A-T undergoing surgery
Patients with A-T may require general anaesthesia for bronchoscopy and bronchoalveolar lavage, lung biopsy,
gastrostomy insertion or scoliosis surgery. There have been scant evidence to date on the anaesthetic risks in
A-T, and a full evaluation should be performed prior to anaesthesia [92, 93]. A protocol for careful assessment
in high-risk ventilator-dependent children with predominantly neuromuscular disorders allowed operative
intervention to be performed under general anaesthesia, minimised post-operative complications and was
associated with a good outcome in the majority [94]. A similar detailed evaluation is undertaken in patients
with A-T by most experts managing these patients. Patients with A-T are at increased risk of aspiration and
some may require post-operative ventilatory support. A-T can be associated with impaired insulin secretion,
increased risk of insulin resistance, glucose intolerance and type 2 diabetes [62, 95, 96]. Peri-operative serum
glucose control monitoring is important with the instigation of appropriate treatment. Use of succinylcholine
may cause hyperkalaemia in patients with significant neuropathy and muscle weakness. The largest series
describes 21 A-T patients who underwent 34 episodes of general anaesthesia for a total of 41 procedures over a
15-year period (1995–2009). Anaesthetic risk was comparable to that for other medically complex paediatric
patients. All patients were seen in a multidisciplinary centre, allowing for disease-specific peri-operative
optimisation and post-operative follow-up. All survived and there were no complications of anaesthesia and no
unexpected admissions to the paediatric intensive care unit. A quarter of the patients required supplemental
oxygen for up to 24 h post-operatively. All patients were anaesthetised within an inpatient hospital setting,
even though 20% were able to go home on the day of surgery. Paediatric intensive care has been shown to be
beneficial for stabilisation and optimisation, especially for emergency procedures [97].
Organisation of care for lung disease in A-T
Respiratory disease in A-T is complex and its understanding and management requires multidisciplinary
input. Current approaches are based on minimal best available evidence in A-T, and extrapolation from
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other more common disorders such as cystic fibrosis. The lung disease of A-T is similar in many ways to
cystic fibrosis in terms of the exacerbation of lung disease and the sequelae (chronic pulmonary sepsis,
bronchiectasis and chronic rhinosinusitis) [23]. Recognising this similarity to patients with cystic fibrosis,
the early involvement of a respiratory physician is desirable to monitor lung function and optimise chest
care, including early aggressive antibiotic treatment, good airway clearance techniques and smoking
cessation advice including avoidance of second-hand smoke [23]. However, the neurological and
immunological contributions to lung disease in A-T are unlike those in cystic fibrosis and this emphasises
the need for multidisciplinary expertise to manage this devastating disease.
Several multidisciplinary clinics across Europe (the UK, Netherlands, Norway, France and Germany) and
elsewhere (Israel, Baltimore (MD, USA) and Brisbane (Australia)) manage patients with A-T. These clinics
provide multidisciplinary expertise for this rare multisystem disease.
Collaboration between these clinics and the establishment of a multinational patient registry and
prospective studies will help determine the outcomes of various prophylactic antibiotic regimes, the
effectiveness of regular versus as-required, and oral versus i.v. antibiotic treatment in A-T. It is hoped that
such collaborations will allow the performance of randomised controlled trials and an improved evidence
base for the disease.
Current practice
Immunology and infections
1) Routine immunological investigations for each patient, including total Ig levels and subclasses, specific
IgG antibodies to tetanus, Haemophilus influenzae B and pneumococcal serotypes and immunophenotyping
of peripheral blood.
2) Since the risks imposed by the development of vaccine-preventable illnesses are potentially fatal, patients
with ataxia telangectasia (A-T) receive all available immunisations to respiratory pathogens (including
pneumococcal polysaccharide vaccine following pneumococcal conjugate vaccine) and inactivated annual
influenza vaccine.
3) A clinical history of susceptibility to infections is considered as more than three respiratory tract
infections (RTIs) per winter season requiring antibiotics or a severe/atypical response to a single infection.
Early aggressive treatment with antibiotics and airway clearance is instituted.
4) If recurrent RTIs present later in life, other contributory factors (e.g. cough/swallowing difficulties,
neuromuscular abnormalities, underlying interstitial lung disease (ILD)) are investigated aggressively.
5) Prophylactic antibiotic treatment is considered when the burden of respiratory infections is high, if there
is associated specific polysaccharide antibody deficiency and when there is established bronchiectasis.
Often the decision is based on the judgement of the caretakers, patient and physician. The advantages
(shorter duration of illness and better quality of life) are weighed against the disadvantages
(microbiological resistance and side-effects).
6) Immune replacement therapy is considered when hypogammaglobulinemia and/or specific antibody
deficiency is present together with a history of recurrent respiratory infections or established
bronchiectasis, or when other preventive measures such as vaccinations and prophylactic antibiotics do
not result in clinical improvement of the RTI symptoms irrespective of the severity of the immunological
abnormalities.
7) Regular surveillance microbiology on respiratory samples is undertaken and early aggressive treatment initiated.
Respiratory monitoring
8) Baseline spirometry is attempted in children who are old enough to perform tests. Regular assessment of
lung function can provide valuable information about subtle progression of lung disease, even in the
absence of clinical symptoms. This is also performed during respiratory illnesses and for peri-operative
assessment and early interventions. Regular assessments at least twice a year provide an impression of
the degree of lung decline and allows for proactive early intervention.
9) Peak cough flow rate as well as forced vital capacity manoeuvres, are considered a mainstay in the
clinical assessment of A-T patients.
10) Regular airway clearance and measures to augment cough and mucociliary clearance is advised by most
experts looking after children with A-T. This is stepped up if respiratory symptoms worsen. Use of nebulised
hypertonic saline or inhaled mannitol may be a useful adjunct to airway clearance in some patients.
11) Overnight polysomnography is considered in adolescents with A-T, particularly in those in whom there is a
clinical suspicion of sleep-related breathing abnormalities, rapid or progressive decline in lung function
or who are developing scoliosis.
12) Progressive, diffuse lung disease that poorly responds to aggressive antibiotic therapy, physiotherapy and
immunoglobulin replacement and to which aspiration does not seem to contribute should lead to
consideration of noninfective causes of lung disease in A-T, including ILD and pulmonary fibrosis and
early treatment with corticosteroids.
Continued
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